<DOC>
	<DOCNO>NCT02561039</DOCNO>
	<brief_summary>This study ass efficacy safety ibandronate ( Bondronat ) , administer intravenously ( IV ) orally ( PO ) , participant malignant bone disease moderate severe pain . Participants randomize receive ibandronate either 6-mg IV infusion every 3 4 week 50-mg tablet PO daily . Pain response Karnofsky Performance Index ( KPI ) measure interval throughout study . The anticipated time study treatment 4 month target sample size 150 individual .</brief_summary>
	<brief_title>A Study Ibandronate ( Bondronat ) Participants With Malignant Bone Disease</brief_title>
	<detailed_description />
	<mesh_term>Bone Diseases</mesh_term>
	<mesh_term>Neoplasm Metastasis</mesh_term>
	<mesh_term>Bone Neoplasms</mesh_term>
	<mesh_term>Ibandronic acid</mesh_term>
	<mesh_term>Diphosphonates</mesh_term>
	<criteria>Adults least 18 year age Malignant bone disease due multiple myeloma cancer lung , prostate , gastrointestinal ( GI ) tract , ovary , bladder Bone pain define Brief Pain Inventory ( BPI ) acute pain score great equal 4 Radiologically confirm bone disease disease Previous treatment ibandronate ( Bondronat ) within previous 2 month Severely impaired renal function Known brain metastasis</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2016</verification_date>
</DOC>